High serum tumor necrosis factor-α levels are associated with lack of response to infliximab in fistulizing Crohn's disease

OBJECTIVES:Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor-α (anti-TNF-α), has been effective in the treatment of patients with active Crohn's disease and with fistulas. We investigated the effect of infliximab on circulating cytokines and acute phase proteins in patients with fistulas to determine the clinical response to anti-TNF-α.METHODS:A total of 36 patients with fistulizing Crohn's disease were selected for study. Serum from patients was drawn before the infusion on day 0 and at wk 2, 4, 6, 8, and 10 after completion of treatment. Circulating concentrations of TNF-α, interleukin-1β (IL-1β), and IL-6 were measured by ELISA. The functional activity of circulating TNF-α was assessed by the WEHI 164 TNF-α bioassay. Acute phase proteins were also determined.RESULTS:Elevated TNF-α, IL-1β, IL-6, and acute phase proteins were observed in patients with Crohn's disease. Of the patients with fistulas, 22 (61.1%) responded to treatment. Before receiving infliximab, higher levels of serum TNF-α were found in patients who did not respond to infliximab compared with those who did (median interquartile range 26, 0–245 pg/ml; n = 14 vs 0, 0–22 pg/ml, n = 22). Patients showed no change in circulating levels of TNF-α during the course of the study.CONCLUSIONS:This treatment produces a clinical improvement in about two-thirds of CD patients with fistulas. The circulating levels of TNF-α are associated with the response to infliximab and could help to identify patients who would benefit from anti-TNF-α treatment.

[1]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[2]  J. Reimund,et al.  Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. , 1996, Gut.

[3]  R. Macdermott,et al.  Enhand secretion of tumour necrosis factor‐alpha, IL‐6, and IL‐1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease , 1993 .

[4]  J. Robotham,et al.  The acute-phase response. , 1995, New horizons.

[5]  B. Scallon,et al.  Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. , 1993, Molecular immunology.

[6]  S. Schreiber,et al.  Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. , 1993, Clinical and experimental immunology.

[7]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[8]  C. J. Taylor,et al.  Matrix metalloproteinase levels are elevated in inflammatory bowel disease. , 1999, Gastroenterology.

[9]  W Domschke,et al.  Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. , 2001, Gastroenterology.

[10]  H. Holtmann,et al.  Soluble forms of tumor necrosis factor receptors (TNF‐Rs). The cDNA for the type I TNF‐R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. , 1990, The EMBO journal.

[11]  T. Macdonald,et al.  Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. , 1993, Gut.

[12]  H. Okamura,et al.  IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-γ dependent manner , 2000, Gut.

[13]  S. Rosewicz,et al.  Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease , 2000, Gut.

[14]  H. Okamura,et al.  Regulation of interferon-γ production by IL-12 and IL-18 , 1998 .

[15]  C. Moskaluk,et al.  IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. , 1998, Journal of immunology.

[16]  A. Fusco,et al.  Bioactive IL-18 expression is up-regulated in Crohn's disease. , 1999, Journal of immunology.

[17]  M. Savage,et al.  Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. , 1991, Gut.

[18]  S. V. van Deventer.  Tumour necrosis factor and Crohn's disease. , 1997, Gut.

[19]  M. Kamm,et al.  Antibodies to tumour necrosis factor α as treatment for Crohn's disease , 2000, The Lancet.

[20]  D. Jewell,et al.  A Simple Classification of Crohn's Disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998 , 2000, Inflammatory bowel diseases.

[21]  D. Jewell,et al.  Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history , 1998, Gut.

[22]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.

[23]  T. Macdonald,et al.  A major role for matrix metalloproteinases in T cell injury in the gut. , 1997, Journal of immunology.

[24]  G. Kollias,et al.  The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. , 1995, Cytokine.

[25]  B. Scallon,et al.  Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions , 1995 .

[26]  P. Rutgeerts,et al.  Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.

[27]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[28]  G. Hartmann,et al.  Taming TNF: strategies to restrain this proinflammatory cytokine. , 1997, Immunology today.

[29]  S. V. Deventer,et al.  Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease , 2001 .

[30]  T. Hibi,et al.  Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. , 2000, Gastroenterology.

[31]  B. Beutler,et al.  Receptor-mediated label-transfer assay (RELAY): a novel method for the detection of plasma tumor necrosis factor at attomolar concentrations. , 1994, Journal of immunological methods.

[32]  A. Ashkenazi,et al.  A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. , 1998, Journal of immunology.

[33]  D. Schuppan,et al.  MMPs in the gut: inflammation hits the matrix , 2000, Gut.

[34]  R. Ricketts.  Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in crohn's ileocolitis: F.J. Baert, G.R. D'Haens, M. Peelers, et al. Gastroenterology 116:22–28 (January), 1999 , 2000 .

[35]  A. Zinsmeister,et al.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.

[36]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[37]  近野 真嗣.  IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-γ dependent manner , 2001 .